Zacks Investment Research Lowers NewLink Genetics (NASDAQ:NLNK) to Hold

Zacks Investment Research cut shares of NewLink Genetics (NASDAQ:NLNK) from a buy rating to a hold rating in a research note released on Wednesday, Zacks.com reports.

According to Zacks, “NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa. “

Separately, ValuEngine downgraded shares of Zosano Pharma from a buy rating to a hold rating in a research note on Wednesday, May 1st. Two analysts have rated the stock with a sell rating and three have issued a hold rating to the company. The company presently has an average rating of Hold and an average target price of $3.75.

Shares of NLNK stock opened at $1.46 on Wednesday. NewLink Genetics has a 12-month low of $1.28 and a 12-month high of $4.95. The company has a market cap of $54.43 million, a P/E ratio of -1.01 and a beta of 1.36. The company’s 50-day moving average price is $1.60. The company has a quick ratio of 13.33, a current ratio of 13.33 and a debt-to-equity ratio of 0.07.

NewLink Genetics (NASDAQ:NLNK) last announced its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.27) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.31) by $0.04. NewLink Genetics had a negative net margin of 1,691.08% and a negative return on equity of 38.63%. The company had revenue of $0.11 million during the quarter. As a group, equities research analysts predict that NewLink Genetics will post -0.1 earnings per share for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Paloma Partners Management Co bought a new position in shares of NewLink Genetics in the fourth quarter worth about $30,000. Pennsylvania Trust Co acquired a new stake in shares of NewLink Genetics during the 1st quarter worth approximately $48,000. Virtu Financial LLC acquired a new stake in shares of NewLink Genetics during the 1st quarter worth approximately $60,000. Rhumbline Advisers grew its position in shares of NewLink Genetics by 41.4% during the 4th quarter. Rhumbline Advisers now owns 40,387 shares of the biotechnology company’s stock worth $61,000 after buying an additional 11,830 shares during the period. Finally, Two Sigma Advisers LP grew its position in shares of NewLink Genetics by 22.6% during the 4th quarter. Two Sigma Advisers LP now owns 110,000 shares of the biotechnology company’s stock worth $167,000 after buying an additional 20,300 shares during the period. 34.30% of the stock is owned by institutional investors.

NewLink Genetics Company Profile

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma.

Featured Article: Depreciation

Get a free copy of the Zacks research report on NewLink Genetics (NLNK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.